Literature DB >> 27343468

Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage.

Yan Li1, Wen Qiu2, Lingjun Zhang2, John Fung3, Feng Lin4.   

Abstract

Mesenchymal stem cells (MSCs) are undergoing intensive testing in clinical trials as a promising new therapy for many inflammatory diseases and for regenerative medicine, but further optimization of current MSC-based therapies is required. In this study, we found that in addition to direct complement-mediated attack through the assembly of membrane attack complexes (MACs) that we and others have recently reported, of the released complement activation products, C5a, but not C3a, activates neutrophils in the blood to further damage MSCs through oxidative burst. In addition, we have developed a simple method for painting factor H, a native complement inhibitor, onto MSCs to locally inhibit complement activation on MSCs. MSCs painted with factor H are protected from both MAC- and neutrophil-mediated attack and are significantly more effective in inhibiting antigen-specific T cell responses than the mock-painted MSCs both in vitro and in vivo.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Complement; Factor H; MSC; Neutrophil; Therapy

Mesh:

Substances:

Year:  2016        PMID: 27343468      PMCID: PMC5290709          DOI: 10.1016/j.biomaterials.2016.05.055

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  44 in total

1.  Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity.

Authors:  Karsten Schnatbaum; Elsa Locardi; Dirk Scharn; Uwe Richter; Heiko Hawlisch; Jochen Knolle; Thomas Polakowski
Journal:  Bioorg Med Chem Lett       Date:  2006-07-28       Impact factor: 2.823

Review 2.  The central role of the alternative complement pathway in human disease.

Authors:  Joshua M Thurman; V Michael Holers
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

3.  Genzyme backs Osiris, despite Prochymal flop.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2009-11       Impact factor: 54.908

4.  Inhibition of neutrophil oxidative burst and granule secretion by wortmannin: potential role of MAP kinase and renaturable kinases.

Authors:  A K Sue-A-Quan; L Fialkow; C J Vlahos; J A Schelm; S Grinstein; J Butler; G P Downey
Journal:  J Cell Physiol       Date:  1997-07       Impact factor: 6.384

Review 5.  Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation.

Authors:  Monica Cortinovis; Federica Casiraghi; Giuseppe Remuzzi; Norberto Perico
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

6.  Structural stability and heat-induced conformational change of two complement inhibitors: C4b-binding protein and factor H.

Authors:  Lena Kask; Bruno O Villoutreix; Mårten Steen; Bala Ramesh; Björn Dahlbäck; Anna M Blom
Journal:  Protein Sci       Date:  2004-04-09       Impact factor: 6.725

7.  Mesenchymal stem cell therapy for treatment of cardiovascular disease: helping people sooner or later.

Authors:  Premal Trivedi; Nancy Tray; Thuy Nguyen; Neha Nigam; G Ian Gallicano
Journal:  Stem Cells Dev       Date:  2010-07       Impact factor: 3.272

8.  Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.

Authors:  S J Collins; F W Ruscetti; R E Gallagher; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

9.  Activation of human neutrophils by C3a and C5A. Comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst.

Authors:  M U Ehrengruber; T Geiser; D A Deranleau
Journal:  FEBS Lett       Date:  1994-06-13       Impact factor: 4.124

10.  Control of the amplification convertase of complement by the plasma protein beta1H.

Authors:  J M Weiler; M R Daha; K F Austen; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

View more
  14 in total

1.  Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis.

Authors:  Yan Li; Fiona Clow; John D Fraser; Feng Lin
Journal:  J Mol Med (Berl)       Date:  2018-07-31       Impact factor: 4.599

2.  The influence of hypoxia and IFN-γ on the proteome and metabolome of therapeutic mesenchymal stem cells.

Authors:  Holly M Wobma; Manuel A Tamargo; Shahar Goeta; Lewis M Brown; Raimon Duran-Struuck; Gordana Vunjak-Novakovic
Journal:  Biomaterials       Date:  2018-03-15       Impact factor: 12.479

3.  Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy.

Authors:  Jijun Xu; Lingjun Zhang; Mian Xie; Yan Li; Ping Huang; Thomas L Saunders; David A Fox; Richard Rosenquist; Feng Lin
Journal:  J Immunol       Date:  2018-04-25       Impact factor: 5.422

Review 4.  Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application.

Authors:  Henry Caplan; Scott D Olson; Akshita Kumar; Mitchell George; Karthik S Prabhakara; Pamela Wenzel; Supinder Bedi; Naama E Toledano-Furman; Fabio Triolo; Julian Kamhieh-Milz; Guido Moll; Charles S Cox
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

5.  Dissecting Allo-Sensitization After Local Administration of Human Allogeneic Adipose Mesenchymal Stem Cells in Perianal Fistulas of Crohn's Disease Patients.

Authors:  Alvaro Avivar-Valderas; Cristina Martín-Martín; Cristina Ramírez; Borja Del Río; Ramón Menta; Pablo Mancheño-Corvo; Maitane Ortiz-Virumbrales; Ángel Herrero-Méndez; Julián Panés; Damián García-Olmo; José Luís Castañer; Itziar Palacios; Eleuterio Lombardo; Wilfried Dalemans; Olga DelaRosa
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

6.  Investigating the effects of IDO1, PTGS2, and TGF-β1 overexpression on immunomodulatory properties of hTERT-MSCs and their extracellular vesicles.

Authors:  Thorsten R Doeppner; Ahmad Reza Bahrami; Azadeh Haghighitalab; Maryam M Matin; Ahmad Amin; Shima Minaee; Hamid Reza Bidkhori
Journal:  Sci Rep       Date:  2021-04-09       Impact factor: 4.379

7.  Mesenchymal stem cells and acellular products attenuate murine induced colitis.

Authors:  Yan Li; Jessica Altemus; Amy L Lightner
Journal:  Stem Cell Res Ther       Date:  2020-11-30       Impact factor: 6.832

Review 8.  Challenges and Strategies for Improving the Regenerative Effects of Mesenchymal Stromal Cell-Based Therapies.

Authors:  Silvia Baldari; Giuliana Di Rocco; Martina Piccoli; Michela Pozzobon; Maurizio Muraca; Gabriele Toietta
Journal:  Int J Mol Sci       Date:  2017-10-02       Impact factor: 5.923

9.  Allogeneic Mesenchymal Stromal Cells (MSCs) are of Comparable Efficacy to Syngeneic MSCs for Therapeutic Revascularization in C57BKSdb/db Mice Despite the Induction of Alloantibody.

Authors:  A Liew; C Baustian; D Thomas; E Vaughan; C Sanz-Nogués; M Creane; X Chen; S Alagesan; P Owens; J Horan; P Dockery; M D Griffin; A Duffy; T O'Brien
Journal:  Cell Transplant       Date:  2018-07-17       Impact factor: 4.064

10.  Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria.

Authors:  Lingjun Zhang; Jin Y Chen; Cassandra Kerr; Brian A Cobb; Jaroslaw P Maciejewski; Feng Lin
Journal:  Leukemia       Date:  2020-08-19       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.